Radiofrequency Ablation for Amiodarone-induced Thyrotoxicosis

• Are adults
• Have overt thyrotoxicosis (within 2 weeks prior to enrollment)
• Are receiving medical therapy for AIT
• Are able to understand the study procedures and to comply with them for the entire length of the study
• Have not normalized their thyroid levels after one month of standard therapy or
• Have persistent and clinically significant thyrotoxicosis (less than 25% decrease in T4 value or patients requiring hospitalization with Congestive heart failure (CHF), tachyarrhythmias, hemodynamic instability or similar co-morbidities) after 2 weeks of standard therapy where additional medical therapy is deemed unlikely to be beneficial or with high risk of side-effects (e.g. hepatotoxicity of antithyroid medications, agranulocytosis of potassium perchlorate or ATD or fluid retention associated with steroids).

Exclusion Criteria:

• Pregnancy
• Patients with prior neck surgery or neck radiation
• Patients with neck anatomy that precludes easy access by RFA to the entirety of thyroid parenchyma
• Patients on anticoagulation therapy
• Patients with comorbidities deemed too high of a risk for general anesthesia
• Treatment with another investigational drug or intervention (within 6 weeks of planned RFA).
• Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
• Inability or unwillingness of individual or legal guardian/representative to give written informed consent.